Payment overview · 2025
General Payments
$154.56
7 reported records · 6 companies
Healthcare provider profile · identity verified
Cheryl Middleton
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HENDERSON, TN · NPI 1851721385
Verified facts
What the public records show
CMS Open Payments records show Cheryl Middleton received $154.56 in general payments during 2025 across 7 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.03 | 30.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.67 | 20.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $29.30 | 19.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.45 | 11.3% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.97 | 9.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.14 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.56 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $47.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.67 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $29.30 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 463 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 437 | 49 |
| Furosemide | Furosemide | 423 | 50 |
| Potassium Chloride | Potassium Chloride | 398 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 40 |
| Famotidine | Famotidine | 376 | 47 |
| Donepezil Hcl | Donepezil Hcl | 292 | 28 |
| Omeprazole | Omeprazole | 292 | 36 |
| Sertraline Hcl | Sertraline Hcl | 256 | 27 |
| Risperidone | Risperidone | 221 | 23 |
| Gabapentin | Gabapentin | 215 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 16 |
| Trazodone Hcl | Trazodone Hcl | 191 | 29 |
| Lisinopril | Lisinopril | 181 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 171 | 22 |
| Losartan Potassium | Losartan Potassium | 169 | 23 |
| Eliquis | Apixaban | 167 | 16 |
| Divalproex Sodium | Divalproex Sodium | 163 | 17 |
| Levetiracetam | Levetiracetam | 160 | 13 |
| Buspirone Hcl | Buspirone Hcl | 156 | 19 |
| Metformin Hcl | Metformin Hcl | 153 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 17 |
| Metformin Hcl Er | Metformin Hcl | 147 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 12 |
| Memantine Hcl | Memantine Hcl | 126 | 17 |
| Allopurinol | Allopurinol | 118 | 15 |
| Januvia | Sitagliptin Phosphate | 118 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 16 |
| Aripiprazole | Aripiprazole | 107 | 13 |
| Carvedilol | Carvedilol | 107 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 15 |
| Alendronate Sodium | Alendronate Sodium | 101 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | suppressed |
| Meloxicam | Meloxicam | 94 | suppressed |
| Lorazepam | Lorazepam | 92 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 91 | 12 |
| Nystatin | Nystatin | 90 | 29 |
| Linzess | Linaclotide | 87 | 15 |
| Clonidine Hcl | Clonidine Hcl | 81 | 11 |
| Simvastatin | Simvastatin | 81 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 79 | suppressed |
| Spironolactone | Spironolactone | 79 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 78 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 71 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 16 |
| Lovastatin | Lovastatin | 60 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | suppressed |
| Alprazolam | Alprazolam | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | suppressed |
| Carbamazepine | Carbamazepine | 52 | suppressed |
| Levofloxacin | Levofloxacin | 52 | 39 |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 51 | suppressed |
| Clonazepam | Clonazepam | 50 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 50 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 11 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Sucralfate | Sucralfate | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Haloperidol | Haloperidol | 43 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 41 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 23 |
| Baclofen | Baclofen | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 32 | suppressed |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 22 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Trimethoprim | Trimethoprim | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 15 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Hydroxyurea | Hydroxyurea | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Finasteride | Finasteride | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ramelteon | Ramelteon | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 11 |
| Letrozole | Letrozole | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Apri | Desogestrel-Ethinyl Estradiol | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Lamotrigine Odt | Lamotrigine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.56 · 7 records | Otsuka America Pharmaceutical, Inc. | Cologuard Collection Kit, NEXPLANON, QULIPTA, Qelbree, REXULTI, UBRELVY, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error